Science Weekly Science Weekly

Narcolepsy: why you’ve been thinking about it all wrong

Oct 6, 2026 · 16m

Summary

This episode of Science Weekly corrects common misconceptions about narcolepsy and explores the recent FDA approval of a first-of-its-kind orexin agonist drug. Host Ian Sample discusses the condition’s true symptoms, including cataplexy and excessive daytime sleepiness, with guest Maddy and patient Julie Flyger. They explain the underlying biology involving the loss of orexin-producing neurons, likely due to an autoimmune response, and how the new therapy targets this root cause rather than just managing symptoms.

Topics discussed

Sponsor: Quo business phone system Sponsor: Washington Wise from Charles Schwab Introduction: Narcolepsy myths and new drug Explaining narcolepsy symptoms and types Personal story: Julie Flyger's sleep paralysis Understanding cataplexy and muscle weakness Daily life impact and driving challenges Current treatments and their limitations Discovery of orexin and narcolepsy biology How orexin regulates sleep-wake cycles The new orexin agonist drug and FDA approval Patient reactions and global impact Sponsor: Radical Thinking from The Guardian Sponsor: Washington Wise from Charles Schwab Future research and unanswered questions Conclusion and credits Recommendation: Slime mold audio long read Sponsor: Thomson Reuters Sponsor: Washington Wise from Charles Schwab Sponsor: Rinse laundry service

More from Science Weekly

Could measles and midterms bring down Maha?
Nov 19, 2026
Nasa’s Voyager 1 probe in sight of an incredible milestone
Nov 17, 2026
Is BMI working? Cop31 latest, the science of great conversation
Nov 12, 2026
Why we get Sad and what helps
Nov 10, 2026
‘Ferritin face’: can you really diagnose low iron from a selfie?
Nov 5, 2026
Listen ad-free on Castria